ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 107 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,009,178 | -40.2% | 50,308 | -15.9% | 0.00% | -50.0% |
| Q2 2023 | $1,687,325 | +162.5% | 59,813 | +60.1% | 0.00% | +100.0% |
| Q1 2023 | $642,747 | -14.6% | 37,369 | +0.0% | 0.00% | 0.0% |
| Q4 2022 | $752,369 | -8.0% | 37,357 | -1.0% | 0.00% | 0.0% |
| Q3 2022 | $818,000 | -17.8% | 37,732 | +6.6% | 0.00% | 0.0% |
| Q2 2022 | $995,000 | +9.9% | 35,393 | +80.3% | 0.00% | 0.0% |
| Q1 2022 | $905,000 | -38.0% | 19,629 | +13.1% | 0.00% | 0.0% |
| Q4 2021 | $1,459,000 | +76.4% | 17,351 | +39.9% | 0.00% | – |
| Q3 2021 | $827,000 | +26.8% | 12,398 | +1.3% | 0.00% | – |
| Q2 2021 | $652,000 | +15.8% | 12,235 | -5.6% | 0.00% | – |
| Q1 2021 | $563,000 | -65.4% | 12,965 | -58.7% | 0.00% | -100.0% |
| Q4 2020 | $1,629,000 | – | 31,374 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |